Elixirr International plc (ELIX) Fair Value & Analysis
Industrials · GB · Market cap 360M GBX
Analysis
Elixirr International plc (ELIX) currently trades at p6.86, while our model-based Fair Value estimate is p8.35 — implying the stock looks roughly 21.7% undervalued today. We read business quality at 95/100 (high quality), in the Industrials sector. Bull case: trading below our estimate, it may offer upside if the fundamentals hold. Bear case: a low price can be a value trap when quality is weak or the data is thin (evidence: high) — always confirm before acting.
About the company
Elixirr International plc, through its subsidiaries, provides management consultancy services in the United Kingdom, the United States, and internationally. It provides services in the areas of AI and machine learning, app design and development, brand identity implementation, brand strategy and positioning, breakthrough imperatives, business and operating modes, business strategy, change management, corporate culture, corporate venture and innovation, customer experience, data and analytics, data strategy, define the C-suite agenda, digital design and build, digital marketing, digital optimization and strategy, enterprise-wide transformation, executive immersions, generative AI, IT strategy, mergers and acquisitions, managed services, onboarding solutions, procurement, product and portfolio management, risk and compliance, sourcing and commercial office, sustainability, target operating model, and transformation management, and transformational leadership. The company serves automo…
Open the full interactive analysis →
Similar stocks
How we calculate Fair Value
Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data — nothing guessed.
Educational research only · not financial advice · no buy/sell recommendation. Model-based estimates are not certainties; their reliability depends on data quality and assumptions.